Long-Term Outcome of Multidisciplinary Versus Standard Gastroenterologist Care for Functional Gastrointestinal Disorders: A Randomized Trial

- Basnayake, Chamara, Kamm, Michael A., Talley, Nicholas J., Liew, Danny, Salzberg, Michael R., Thompson, Alexander J., Stanley, Annalise, Wilson-O'Brien, Amy, Burrell, Kathryn, Lees-Trinca, Isabella, Khera, Angela, Kantidakis, Jim, Wong, Olivia, Fox, Kate

Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial

- Basnayake, Chamara, Kamm, Michael A., Stanley, Annalise, Wilson-O'Brien, Amy, Burrell, Kathryn, Lees-Trinca, Isabella, Khera, Angela, Kantidakis, Jim, Wong, Olivia, Fox, Kate, Talley, Nicholas J., Liew, Danny, Salzberg, Michael R., Thompson, Alexander J.

Predictors of disability worsening in clinically isolated syndrome

- Jokubaitis, Vilija G., Spelman, Tim, Cabrera-Gomez, José, Oreja-Guevara, Celia, Boz, Cavit, Giuliani, Giorgio, Fernández-Bolaños, Ricardo, Iuliano, Gerardo, Lechner-Scott, Jeannette, Verheul, Freek, van Pesch, Vincent, Petkovska-Boskova, Tatjana, Kalincik, Tomas, Fiol, Marcela, Moore, Fraser, Cristiano, Edgardo, Alroughani, Raed, Bergamaschi, Roberto, Barnett, Michael, Slee, Mark, Vella, Norbet, Herbert, Joseph, Shaw, Cameron, Izquierdo, Guillermo, Saladino, Maria Laura, Amato, Maria Pia, Liew, Danny, Paolicelli, Damiano, Butzkueven, Helmut, Trojano, Maria, Grand'Maison, François, Duquette, Pierre, Girard, Marc, Lugaresi, Alessandra, Grammond, Pierre, Hupperts, Raymond

Fingolimod after natalizumab and the risk of short-term relapse

- Jokubaitis, Vilija G., Li, Vivien, Barnett, Michael, Grand'Maison, Francois, Trojano, Maria, Slee, Mark, Giuliani, Giorgio, Shaw, Cameron, Boz, Cavit, Spitaleri, Daniele L. A., Verheul, Freek, Haartsen, Jodi, Kalincik, Tomas, Liew, Danny, Butzkueven, Helmut, Izquierdo, Guillermo, Hodgkinson, Suzanne, Alroughani, Raed, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Duquette, Pierre, Girard, Marc

Risk of relapse phenotype recurrence in multiple sclerosis

- Kalincik, Tomas, Buzzard, Katherine, Oreja-Guevara, Celia, Boz, Cavit, Hupperts, Raymond, Petersen, Thor, Giuliani, Giorgop, Iuliano, Gerardo, Lechner-Scott, Jeannette, Barnett, Michael, Bergamaschi, Roberto, Van Pesch, Vincent, Jokubaitis, Vilija, Amato, Maria Pia, van Munster, Erik, Fernandez-Bolanos, Ricardo, Verheul, Freek, Fiol, Marcela, Cristiano, Edgardo, Slee, Mark, Rio, Maria Edite, Spitaleri, Daniele, Alroughani, Raed, Trojano, Maria, Gray, Orla, Saladino, Maria Laura, Flechter, Sholmo, Herbert, Joseph, Cabrera-Gomez, Jose Antonio, Vella, Norbert, Paine, Mark, Shaw, Cameron, Moore, Fraser, Vucic, Steve, Duquette, Pierre, Savino, Aldo, Singhal, Bhim, Petkovska-Boskova, Tatjana, Parratt, John, Sirbu, Carmen-Adella, Rozsa, Csilla, Liew, Danny, Butzkueven, Helmut, Izquierdo, Guillermo, Girard, Marc, Lugaresi, Alessandra, Grammond, Pierre, Grand'Maison, Francois

The Australian Multiple Sclerosis (MS) Immunotherapy Study: a prospective, multicentre study of drug utilisation using the MSBase platform

- Jokubaitis, Vilija G., Spelman, Tim, Lechner-Scott, Jeannette, Barnett, Michael, Shaw, Cameron, Vucic, Steve, Liew, Danny, Butzkueven, Helmut, Slee, Mark, Australian MSBase Study Group